RxDoctor Payments Data

Rommaan Ahmad, DO

Physical Medicine & Rehabilitation · Clinton, MDNPI 1558439133

Payments from drug & device makers

$279in general payments, 2019–2025

Across 10 payments — averaging $27.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$91
  • Electronic Waveform Lab, Inc.$66
  • Amgen$41
  • Vertex$29
  • IBSA Pharma Inc.$21
  • Scilex Pharmaceuticals Inc.$18
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$279100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Collegium Pharmaceutical, Inc.4$91
Electronic Waveform Lab, Inc.1$66
Amgen1$41
Vertex1$29
IBSA Pharma Inc.1$21
Scilex Pharmaceuticals Inc.1$18
Zimmer Biomet1$12

How this compares

$279 in reported general payments places this provider in the 60th percentile of 202 physical medicine & rehabilitation providers in Maryland.

See all physical medicine & rehabilitation providers in Maryland

Medicare billing

Part B allowed, 2024
$116,178
Medicare patients
206
Services billed
1,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate24$35,385
OxycontinOxycodone Hcl26$27,812
Lidocaine89$21,320
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen445$16,197
Oxycodone Hcl465$11,054
Pregabalin225$7,412
Diclofenac Sodium46$7,081
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen210$6,630
Morphine Sulfate ErMorphine Sulfate138$6,236
MovantikNaloxegol Oxalate13$5,752
Fentanyl60$4,678
Gabapentin180$3,277
Cyclobenzaprine Hcl139$2,270
Zolpidem Tartrate90$1,723
Tizanidine Hcl68$1,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$91$35,38524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 202 physical medicine & rehabilitation providers in Maryland.

Other physical medicine & rehabilitation in Clinton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →